" /> Tislelizumab - CISMeF





Preferred Label : Tislelizumab;

NCIt synonyms : Tirelizumab; Tislelizumab-jsgr;

NCIt definition : A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.;

UNII : 0KVO411B3N;

CAS number : 1858168-59-8;

Drug name : Tevimbra;

Molecule name : BGB-A317; BGB A317;

Codes from synonyms : 64463;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
07/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.